Immunotherapies and gene therapies
The company is developing therapies in response to demand for better-performing cholesterol-lowering treatments for cardiovascular disease.
Source: LinkedIn company description · Retrieved October 13, 2026
Ameliogenix is a biotechnology company in Ottawa, Canada, founded in 2023, focused on developing immunotherapies and gene therapies for complex disorders.
Its current efforts address demand for cholesterol-lowering therapies for cardiovascular disease.
Based on the company’s public LinkedIn information, supplied through RevenueBase.
The company is developing therapies in response to demand for better-performing cholesterol-lowering treatments for cardiovascular disease.
Source: LinkedIn company description · Retrieved October 13, 2026
The company is developing AGXV Series mRNA therapies that synergistically rewire cholesterol metabolism.
Source: LinkedIn company description · Retrieved October 13, 2026
Supported appearances on published RevenueBase lists, including available memberships beyond displayed rankings.
Positions describe ordering within each source list. See how lists are built ↗
Embeddable award for your website
RevenueBase prepared this profile from the company’s public LinkedIn information and RevenueBase company data. These source records were retrieved on October 13, 2026. AI helped summarize these sources, with a separate automated check against the source text completed on November 4, 2026. Directory positions use company-contact counts from separate saved list snapshots dated September 15, 2026, September 19, 2026 and September 21, 2026. How the company lists are built.
Share a correction, your relationship to the company, and supporting sources. Requests are reviewed before changes are published.
Explore more companies by name, headquarters and business focus.